Drug Profile
Research programme: monoclonal antibody therapeutics - Gmax Biopharm
Alternative Names: GMA 103; GMA 104Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Gmax Biopharm
- Class Analgesics; Antihyperglycaemics; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in China (Parenteral)
- 01 Nov 2017 Research programme: monoclonal antibody therapeutics - Gmax Biopharm is available for licensing in World as of 01 Nov 2017. http://www.gmaxbiopharm.com/job.html
- 01 Nov 2017 Preclinical trials of GMA 103 in Type-2 diabetes mellitus in China (Parenteral) (Gmax Biopharm pipeline, November 2017)